Koninklijke DSM
Market Cap
€24.5b
Last Updated
2021/03/08 20:34 UTC
Data Sources
Company Financials +
Executive Summary
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of Asia, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet second-rate dividend payer.
Similar Companies
Share Price & News
How has Koninklijke DSM's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DSM is less volatile than 75% of Dutch stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: DSM's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
1.9%
DSM
0.7%
NL Chemicals
-0.8%
NL Market
1 Year Return
41.9%
DSM
37.4%
NL Chemicals
40.4%
NL Market
Return vs Industry: DSM exceeded the Dutch Chemicals industry which returned 26.9% over the past year.
Return vs Market: DSM exceeded the Dutch Market which returned 25.5% over the past year.
Shareholder returns
| DSM | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.9% | 0.7% | -0.8% |
| 30 Day | -3.5% | -1.8% | 1.5% |
| 90 Day | 4.2% | 3.4% | 9.3% |
| 1 Year | 44.8%41.9% | 40.4%37.4% | 43.0%40.4% |
| 3 Year | 86.4%74.4% | 48.1%29.1% | 22.3%10.1% |
| 5 Year | 233.4%194.7% | 131.7%88.8% | 65.8%35.2% |
Long-Term Price Volatility Vs. Market
How volatile is Koninklijke DSM's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Are Koninklijke DSM N.V.'s (AMS:DSM) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?3 weeks ago | Simply Wall St
Koninklijke DSM (AMS:DSM) Has Gifted Shareholders With A Fantastic 276% Total Return On Their Investment1 month ago | Simply Wall St
Have Insiders Been Selling Koninklijke DSM N.V. (AMS:DSM) Shares?Valuation
Is Koninklijke DSM undervalued compared to its fair value and its price relative to the market?
54.5x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DSM (€142.35) is trading above our estimate of fair value (€113.92)
Significantly Below Fair Value: DSM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DSM is poor value based on its PE Ratio (54.5x) compared to the NL Chemicals industry average (26x).
PE vs Market: DSM is poor value based on its PE Ratio (54.5x) compared to the Dutch market (26x).
Price to Earnings Growth Ratio
PEG Ratio: DSM is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: DSM is overvalued based on its PB Ratio (3.3x) compared to the NL Chemicals industry average (3x).
Next Steps
Future Growth
How is Koninklijke DSM forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
16.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DSM's forecast earnings growth (16.7% per year) is above the savings rate (0.2%).
Earnings vs Market: DSM's earnings (16.7% per year) are forecast to grow slower than the Dutch market (26.5% per year).
High Growth Earnings: DSM's earnings are forecast to grow, but not significantly.
Revenue vs Market: DSM's revenue (5.3% per year) is forecast to grow slower than the Dutch market (10.2% per year).
High Growth Revenue: DSM's revenue (5.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DSM's Return on Equity is forecast to be low in 3 years time (12.3%).
Next Steps
Past Performance
How has Koninklijke DSM performed over the past 5 years?
3.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DSM has high quality earnings.
Growing Profit Margin: DSM's current net profit margins (5.5%) are lower than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: DSM's earnings have grown by 3.7% per year over the past 5 years.
Accelerating Growth: DSM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DSM had negative earnings growth (-33.7%) over the past year, making it difficult to compare to the Chemicals industry average (7%).
Return on Equity
High ROE: DSM's Return on Equity (6.1%) is considered low.
Next Steps
Financial Health
How is Koninklijke DSM's financial position?
Financial Position Analysis
Short Term Liabilities: DSM's short term assets (€5.4B) exceed its short term liabilities (€2.3B).
Long Term Liabilities: DSM's short term assets (€5.4B) exceed its long term liabilities (€4.6B).
Debt to Equity History and Analysis
Debt Level: DSM's debt to equity ratio (45.1%) is considered high.
Reducing Debt: DSM's debt to equity ratio has reduced from 53.5% to 45.1% over the past 5 years.
Debt Coverage: DSM's debt is well covered by operating cash flow (44.3%).
Interest Coverage: DSM's interest payments on its debt are well covered by EBIT (9.2x coverage).
Balance Sheet
Next Steps
Dividend
What is Koninklijke DSM current dividend yield, its reliability and sustainability?
1.69%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DSM's dividend (1.69%) isn’t notable compared to the bottom 25% of dividend payers in the Dutch market (1.88%).
High Dividend: DSM's dividend (1.69%) is low compared to the top 25% of dividend payers in the Dutch market (4.51%).
Stability and Growth of Payments
Stable Dividend: DSM's dividends per share have been stable in the past 10 years.
Growing Dividend: DSM's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (91.9%), DSM's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: DSM's dividends in 3 years are forecast to be well covered by earnings (46.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.0yrs
Average management tenure
CEO
Dimitri de Vreeze (53 yo)
1.08yrs
Tenure
€2,639,000
Compensation
Mr. Dimitri de Vreeze serves as Chief Operating Officer of DSM Nutritional Products AG. He serves as President of DSM Resins at DSM-AGI Corporation. He has been a Member of Management Board at Koninklijke ...
CEO Compensation Analysis
Compensation vs Market: Dimitri's total compensation ($USD3.13M) is about average for companies of similar size in the Dutch market ($USD3.14M).
Compensation vs Earnings: Dimitri's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO, COO & Member of the Managing Board | 1.08yrs | €2.64m | 0.061% € 15.0m | |
| Co-CEO, CFO & Member of the Managing Board | 1.08yrs | €2.60m | 0.061% € 14.8m | |
| Senior VP of Corporate Control & Accounting and Group Controller | 8.58yrs | no data | no data | |
| Chief Technology Officer | 3.92yrs | no data | no data | |
| Vice President of Investor Relations | 8.67yrs | no data | no data | |
| Director of Legal Affairs and General Counsel | 8.92yrs | no data | no data | |
| Senior Communications Manager | no data | no data | no data | |
| Executive Vice President of People & Organization | 0.50yr | no data | no data | |
| Head of Energie Beheer Nederland | no data | no data | no data | |
| President & CEO of Nutritional Products | 8.17yrs | €87.56k | no data | |
| Head of Manufacturing & Purchasing of DSM Nutritional Products | no data | no data | no data | |
| Senior Vice President of Nutrition Science & Advocacy | no data | no data | no data |
6.0yrs
Average Tenure
64yo
Average Age
Experienced Management: DSM's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 3.83yrs | €96.75k | no data | |
| Member of Sustainability Advisory Board & Honorary Chairman | 1yr | €3.35m | 0.15% € 36.3m | |
| Independent Chairman of Supervisory Board | 9.92yrs | €128.75k | no data | |
| Independent Member of Supervisory Board | 3.83yrs | €98.25k | 0.00061% € 149.5k | |
| Independent Deputy Chairwoman of Supervisory Board | no data | €98.75k | 0.00089% € 218.2k | |
| Member of Sustainability Advisory Board | no data | no data | no data | |
| Member of Sustainability Advisory Board | no data | no data | no data | |
| Independent Member of Supervisory Board | 8.83yrs | €98.75k | no data | |
| Independent Member of Supervisory Board | 4.92yrs | €96.75k | no data | |
| Member of Sustainability Advisory Board | no data | no data | no data | |
| Member of Sustainability Advisory Board | 5.08yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.9yrs
Average Tenure
63yo
Average Age
Experienced Board: DSM's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Koninklijke DSM N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Koninklijke DSM N.V.
- Ticker: DSM
- Exchange: ENXTAM
- Founded: 1902
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: €24.515b
- Shares outstanding: 172.22m
- Website: https://www.dsm.com
Number of Employees
Location
- Koninklijke DSM N.V.
- Het Overloon 1
- Heerlen
- Limburg
- 6411 TE
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DSM | ENXTAM (Euronext Amsterdam) | Yes | Ordinary Shares | NL | EUR | Jan 1992 |
| DSM2 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| DSM | BRSE (Berne Stock Exchange) | Yes | Ordinary Shares | CH | CHF | Jan 1992 |
| KDSK.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| DSM2 | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| 0NPP | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| DSMA | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| RDSM | WBAG (Wiener Boerse AG) | Yes | Ordinary Shares | AT | EUR | Jan 1992 |
| DSM N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Jan 1992 |
| RDSM.Y | OTCPK (Pink Sheets LLC) | ADR-EACH 4 CNV INTO 1 ORD EUR1.5 | US | USD | Sep 1995 | |
| DSM | DB (Deutsche Boerse AG) | ADR-EACH 4 CNV INTO 1 ORD EUR1.5 | DE | EUR | Sep 1995 |
Biography
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/08 20:34 |
| End of Day Share Price | 2021/03/08 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.